Physician profile
Rhonda Gilbert
NPI 1245767128
$5,193.22
in general payments reported to CMS, 2019-2025
35 companies · $1,460 in 2025
The $1,460 reported for 2025 was more than what 92% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $535 · 2022: $858 · 2023: $1,005 · 2024: $1,335 · 2025: $1,460.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,800.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,800.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $811.83 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Pfizer INC. | $759.96 | 2022-2025 | |
| Abbvie INC. | $706.21 | 2021-2025 | |
| Lilly USA, LLC | $561.30 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $374.84 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Amgen INC. | $178.14 | 2022-2025 | Repatha, Otezla, Repatha |
| Astrazeneca Pharmaceuticals LP | $163.19 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $153.19 | 2021-2023 | Jardiance |
| Abbott Laboratories | $147.87 | 2022-2025 | Freestyle Libre 3 |
| Xeris Pharmaceuticals, INC. | $137.93 | 2021-2025 | Gvoke Hypopen |
| Exact Sciences Corporation | $132.57 | 2023-2024 | Cologuard Collection Kit |
| Takeda Pharmaceuticals U.S.A., INC. | $119.81 | 2021 | |
| Merck Sharp & Dohme LLC | $117.04 | 2022-2023 | Verquvo, Belsomra, Steglatro |
| Bayer Healthcare Pharmaceuticals INC. | $90.03 | 2022-2023 | |
| Sanofi-Aventis U.S. LLC | $78.18 | 2021-2023 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $73.97 | 2024-2025 | Voquezna |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $68.93 | 2025 | Caplyta |
| Esperion Therapeutics, INC. | $66.70 | 2021-2024 | Nexletol |
| Novartis Pharmaceuticals Corporation | $55.27 | 2022-2023 | |
| Otsuka America Pharmaceutical, INC. | $51.48 | 2023-2024 | Rexulti |
| Sumitomo Pharma America, INC. | $43.11 | 2023-2025 | Gemtesa |
| Dexcom, INC. | $41.39 | 2021-2025 | Dexcom G6 Transmitter |
| Shield Therapeutics INC | $39.49 | 2022-2024 | |
| Lundbeck LLC | $29.28 | 2022-2023 | Rexulti |
| Axsome Therapeutics, INC. | $26.07 | 2025 | Auvelity |
| Corcept Therapeutics | $24.97 | 2025 | Korlym |
| Inspire Medical Systems, INC. | $21.65 | 2025 | Inspire |
| Optinose US, INC. | $18.46 | 2021 | |
| Bausch Health US, LLC | $17.04 | 2021 | |
| Ironshore Pharmaceuticals INC. | $16.52 | 2023 | Jornay Pm |
| Kowa Pharmaceuticals America, INC. | $14.78 | 2021 | |
| Neos Therapeutics, LP | $14.16 | 2024 | Adzenys Xr-Odt |
| Verona Pharma, INC. | $14.06 | 2025 | Ohtuvayre |
| Eisai INC. | $12.23 | 2021 | |
| Supernus Pharmaceuticals, INC. | $11.57 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rhonda Gilbert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.